 DARTMOUTH, Nova Scotia--BUSINESS WIRE-- DLBCL--IMV Inc. Nasdaq: IMV; TSX: IMV IMV or the Company, a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that, following feedback from the U.S. Food Drug Administration FDA, the company has entered into an agreement with Merck to initiate a Phase 2B clinical trial to evaluate its lead compound, maveropepimut-S DPX-Survivac in combination with KEYTRUDA pembrolizumab, Mercks ant 